

November 29, 2018



## Abeona Therapeutics to Host R&D Day on December 6, 2018

NEW YORK and CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced it will host its 2nd R&D Day event for the institutional investment community in New York on Thursday, December 6, 2018. The formal program is scheduled to begin at 8:45 am ET and conclude at 1:00 pm ET. A live webcast of the event will be available on the investor relations section of Company's website at [www.abeonatherapeutics.com](http://www.abeonatherapeutics.com). The program will include presentations and panel discussions featuring senior management, clinical investigators and key opinion leaders on current topics in gene therapy.

### **About Abeona**

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates. For more information, visit [www.abeonatherapeutics.com](http://www.abeonatherapeutics.com).

### **Investor Contact:**

Christine Silverstein  
SVP, Finance & Investor Relations  
Abeona Therapeutics Inc.  
+1 (646) 813-4707  
[csilverstein@abeonatherapeutics.com](mailto:csilverstein@abeonatherapeutics.com)

### **Media Contact:**

Scott Santiamo  
Director, Corporate Communications  
Abeona Therapeutics Inc.  
+1 (718) 344-5843  
[ssantiamo@abeonatherapeutics.com](mailto:ssantiamo@abeonatherapeutics.com)



Source: Abeona Therapeutics Inc.